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Protein surface mimetics: understanding how ruthenium 
tris(bipyridines) interact with proteins 
Sarah H. Hewitt, Maria H. Filby, Ed Hayes, Lars T. Kuhn, Arnout P. Kalverda, Michael E. Webb and 
Andrew J. Wilson* 
Abstract: Protein surface mimetics achieve high affinity binding by 
exploiting a scaffold to project binding groups over a large area of 
solvent exposed protein surface to make multiple co-operative non-
covalent interactions. Such recognition is a pre-requisite for 
competitive/ orthosteric inhibition of protein-protein interactions 
(PPIs). This paper describes biophysical and structural studies on 
ruthenium(II) tris(bipyridine) surface mimetics that recognize 
cytochrome (cyt) c and inhibit the cyt c/ cyt c peroxidase (CCP) PPI. 
Binding is electrostatically driven, with enhanced affinity achieved 
through enthalpic contributions thought to arise from the ability of the 
surface mimetics to make a greater number of non-covalent 
interactions with surface exposed basic residues on cyt c in 
comparison to CCP. High field natural abundance 1H-15N HSQC 
NMR experiments are consistent with surface mimetics binding to 
cyt c in similar manner to CCP. This provides a framework for 
understanding recognition of proteins by supramolecular receptors 
and informing the design of ligands superior to the protein partners 
upon which they are inspired.  
Introduction 
Protein-protein interactions (PPIs) are considered difficult to 
inhibit using conventional synthetic molecules;[1,2] they typically 
involve large interfaces with few discernable pockets on either 
partner that represent the hallmark of traditional ligandable[3] 
proteins.[4] Given conventional approaches for ligand discovery 
e.g. high-throughput screening and fragment based drug 
discovery have met with limited success in identifying PPI 
inhibitors,[5,6]  supramolecular chemical biology[7] with a focus on 
understanding and controlling molecular recognition is well 
placed to elaborate new strategies. One such strategy is the 
surface mimetic approach;[8±10] protein surface mimetics are a 
class of molecular structure that utilize a scaffold to project 
multiple binding groups over a large area of protein surface and 
achieve high affinity protein binding. Several different scaffolds 
have been used as protein surface mimetics, including 
calixarenes,[11±15] porphyrins,[8,16±18] dendrimers,[19±23] metal 
complexes,[9,24,25] nanoparticles,[26±28] and others.[29±33] 
Figure 1. The Ru(II)(bpy)3 surface mimetics and their PPI counterparts, cyt c 
and CCP  (A) Ru(II)(bpy)3 complexes 1 and 2, (B) the cyt c/ CCP interaction, 
cyt c in red, CCP in purple (PDB ID 1U75)[34] and (C) the interaction faces of  
cyt c (left) and CCP (right), showing a ring (red circle) of basic amino acid 
residues (blue) on cyt c and a complementary patch (blue circle) on CCP with 
acidic amino acid residues (red) 
 
We and others previously introduced highly functionalized 
ruthenium(II) tris(bipyridine) (Ru(II)(bpy)3) complexes as protein 
surface mimetics.[35±41] These large, multivalent, luminescent 
molecules have a chemically inert core, which can be 
peripherally functionalized with different binding groups in a 
stereochemically and geometrically rich manner. Hamachi and 
coworkers initially designed a carboxylate functionalized 
Ru(II)(bpy)3 complex capable of binding to cytochrome (cyt) c 
and mediating photoreduction.[35] Subsequently our group and 
the Ohkanda group designed high affinity Ru(II)(bpy)3 
complexes for binding to cyt c DQGĮ-chymotrypsin.[36±42] In our 
initial study of five different Ru(II)(bpy)3 complexes, two 
carboxylic acid functionalized complexes (Figure 1A, complex 1 
and 2) were shown to recognize cyt c with nanomolar affinity 
and do so selectively over acetylated cyt c and four other 
proteins.[36] Complex 2 was also shown to destabilize cyt c.[39] 
Analysis of Ru(II)(bpy)3 FRPSOH[HV ZLWK ¶-monosubstituted 
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Scheme 1. Synthesis of the Ru(II)(bpy)3 complex
bipyridine ligands showed a difference in binding affinity 
between fac and mer LVRPHUV  Q0 YHUVXV  Q0 IRU ǻ- 
LVRPHUV UHVSHFWLYHO\ EXW OLWWOH GLIIHUHQFH EHWZHHQ ǻ DQG ȁ
isomers (25 nM versus 29 nM for mer isomers respectively), 
establishing that geometrical shape affects binding.[37] The 
Ohkanda group used heteroleptic complexes to propose that 
four of the six arms of Ru(II)(bpy)3 complexes bearing bpy 
groups with two substituents interact with cyt c.[41] Further 
studies have shown that these complexes are able to enter cells, 
with little cytotoxicity.[38,41]  
These prior strategies employed a rudimentary design that 
exploits charge complementarity with the cyt c surface;[36,37,43] 
multiple carboxylic acids are present in order to complement 
surface exposed basic residues on cyt c. However evidence of 
PPI inhibition,[26,44] detailed information on the nature of binding 
and any structural information are lacking, which is characteristic 
of all but a few studies on protein surface recognition using 
classic supramolecular scaffolds.[18,45,46] Inhibited ascorbate 
reduction of cyt c,[36,37] is consistent with binding to the CCP 
binding site i.e. the haem-exposed edge of cyt c, where there is 
a hydrophobic patch surrounded by a ring of basic amino acid 
residues.[47] Herein, we show that highly functionalized 
Ru(II)(bpy)3 complexes inhibit the cyt c/ CCP interaction and do 
so through electrostatically and entropically driven binding of cyt 
c in a manner that replicates the binding of cyt c by CCP. Higher 
affinity Ru(II)(bpy)3 complexes achieve additional potency 
through enthalpic effects. Finally, using high field NMR we 
demonstrate that recognition occurs at the haem exposed edge 
and hence PPI inhibition is orthosteric. Collectively, this provides 
a more rational framework for the design of supramolecular 
receptors for cyt c and protein-surfaces more widely. 
Results and Discussion 
Synthesis 
Ru(II)(bpy)3 synthesis proceeds via the route shown in Scheme 
1, using a tert-butyl ester or methyl ester protecting group 
strategy for complex 1 or 2 respectively. In this generic route, 
the ligand is first assembled by amide bond formation, via a 
water sensitive acid chloride, with subsequent complexation 
XVLQJ:LONLQVRQ¶VUHDJHQW[48] The protected complex formed can 
be purified via conventional silica flash column chromatography. 
Subsequent deprotection with TFA or LiOH affords complexes 1 
and 2 respectively. Deprotection of the larger complex 2 requires 
mild conditions and careful reaction monitoring due to the lability 
of the anilide bond under both basic and acidic conditions. 
Complex 2 inhibits the cyt c/ CCP PPI 
Figure 2. Complex 2 inhibits the cyt c/CCP PPI (A) luminescence data (Ȝex = 
430 nm, 2 µM ZnCCP (orange), + 2 µM cyt c SLQNVKRZVORVVRIȜmax at 595 
nm, + 2 µM cyt c and 4 µM 2 (green) shows recovery RIȜmax at 595 nM and 
UHGXFHGȜmax at 625 nM relative to 4 µM 2 alone (blue) 
 
Given that the affinity of complex 2 for cyt c which we previously 
reported,[36] is greater than that of CCP for cyt c[49] we 
anticipated 2 would be a potent inhibitor of the cyt c/ CCP 
interaction. A luminescence quenching assay was implemented 
(Fig. 2) wherein the luminescence emission from Zn-
protoporphyrin substituted CCP[50] is first quenched upon 
interaction with cyt c and then recovered upon displacement with 
the ruthenium complex. Signal overlap with the Ru(II)(bpy)3 
luminescence Ȝmax~625 nm) complicates interpretation, 
however simultaneous loss of MLCT luminescence is observed 
ChemBioChem 10.1002/cbic.201600552
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relative to the complex in the absence of cyt c. A native agarose 
gel supports successful PPI inhibition (see ESI, Fig. S1).  
Binding is Entropically favourable and electrostatic in 
nature. 
Figure 3 9DQ¶W +RII DQG Debye-Hückel analysis on the binding interactions 
between cyt c and complexes 1 and 2, (a) Representative YDQ¶W+RIIDQDO\VLV
binding in 5 mM sodium phosphate, 0.2 mg mL-1 BSA, pH 7.5, temperature 
range 25 to 45 °C, (errors in curve fitting for a single replicate are shown) (b) 
Debye-Hückel analysis, using the Güntelberg approximation, binding in 5 mM 
sodium phosphate, 0.2 mg mL-1 BSA, pH 7.5, and variable concentrations 
NaCl, (variation in Kd from two replicates is shown)  
 
The binding affinities of complexes 1 and 2 towards cyt c were 
measured using a luminescence quenching assay,[36] where the 
luminescence of the ruthenium complexes is quenched on 
binding to cyt c through photoinduced electron transfer to its 
haem group. Previously, cuvette-based fluorescence was used 
for binding studies,[36,37] however optimization of the assay on a 
384 well plate was required for higher-throughput screening of 
the binding under different conditions. Addition of a blocking 
agent, bovine serum albumin (BSA), was found to be required to 
allow for agreement between the two methods. The addition of 
BSA accompanied a concurrent decrease in binding affinity 
(from Kd 10.5 ± 0.4 nM to 42.9 ± 3.1 nM for complex 2) (See ESI 
Fig. S1). Determination of Kd at different temperatures and 
subsequent vDQ¶W +RII DQDO\Ves (Figure 3A) provided 
thermodynamic parameters (Table 1) for binding (Equation 1), 
making the assumption that ǻ+ DQG ǻ6 DUH temperature-
independent 
             Eq. 1 
These data show that for complex 1 binding to cyt c is 
primarily driven by entropic contributions with a small favorable 
enthalpic contribution, whereas for complex 2 it is both 
entropically and enthalpically driven. In comparison the cyt c/ 
CCP interaction is entropically driven, and enthalpically is mildly 
unfavourable.[49] Thus, complex 1, with fewer carboxylates, more 
closely matches the thermodynamic profile of CCP in binding to 
cyt c. A plausible hypothesis for enhanced binding of complex 2 
to cyt c, is that the additional carboxylic acids form increased 
numbers of salt bridges with the basic amino acids on the cyt c 
surface. 
 
Table 1. 7KHUPRG\QDPLFSDUDPHWHUVGHULYHGIURPWKHYDQ¶W+RIIDQDOysis for 
the binding of complexes 1 and 2 to cyt c (errors derived from triplicate 
experiments), and literature values for the cyt c/CCP interaction under similar 
conditions[49] 
 Complex 1 Complex 2 CCP[49] 
ǻ+N-PRO-1 -6.6 ± 0.4 -26.3 ± 3.0 9.4 ± 0.8 
7ǻ6&N-PRO-1 24.5 ± 0.4 16.0 ± 3.0 38.4 ± 0.9 
ǻ*C) / kJ mol-1 -31.0 ± 0.4 -42.3 ± 0.0 -27.9 ± 1.0 
 
Table 2. Binding in variable ionic strengths, 5 mM sodium phosphate, 0.2 mg 
mL-1 BSA, pH 7.5, variable concentration NaCl, nd=not determined  
Ionic strength/ mM Complex 1 Kd ȝ0 Complex 2 Kd/ nM 
8.39 2.88 ± 0.46 25.3 ±  2.4 
13.39 4.25 ± 0.47 64.8 ±  13.7 
18.39 10.30 ± 1.61 196.5 ±  59.2 
28.39 20.23 ± 0.16 426.5 ± 59.8 
48.39 nd 2040.9 ± 152.6 
 
To further understand the electrostatic contribution to 
binding, affinities were determined at different ionic strength (I). 
Cyt c binding by both complex 1 and 2 is highly dependent upon 
ionic strength (Table 2), with binding affinity decreasing on 
increasing ionic strength, suggesting electrostatics dominate 
binding. The Kd values could be fit to the Debye-Hückel 
relationship (Eq. 2) (Figure 3(B)), in this case using a Güntelberg 
approximation (Eq. 3), which is valid up to I = 100 mM.  
   Eq. 2 
   Eq. 3 
From this relationship the parameters Kd0 and Z1Z2 can be 
established (Table 3), providing an estimate of the affinity at I = 
0 and the product of the interacting positive and negative 
charges. The data were consistent with the Güntelberg 
approximation for both complexes (Figure 3B), and the 
calculated values of Kd0 show high affinity binding for complex 2 
and weaker binding for complex 1 at zero ionic strength. The 
product, Z1Z2, provides an indication of the charges involved in 
the interaction, with complex 2 having a larger value than 
complex 1 and CCP. Using these data, the charge on the 
complex interacting with cyt c can be estimated. A rudimentary 
interpretation of this date is made possible by assuming that cyt 
c has the same charge in all cases (calculated to be ~6 at pH 
7.5);[51] the charge on complex 1, 2 and CCP can thus be 
ChemBioChem 10.1002/cbic.201600552
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calculated as 4.3, 5.9 and 4.8, respectively. Complex 1 and CCP 
have relatively similar charges, suggesting they make similar 
electrostatic interactions with cyt c. Complex 2 has a larger 
charge indicating increased electrostatic interactions with cyt c. 
7KLV LV FRQVLVWHQW ZLWK WKH YDQ¶W +RII DQDO\VHV Accounting for 
the crudeness of the Debye-Hückel approximation where small 
(~3 Å), evenly dispersed charges are assumed (even when 
using the Güntelberg extension), the data indicate that perhaps 
not all carboxylates are deprotonated under the assay conditions 
(i.e. pH 7.4) and/or that a limited number of carboxylates are 
needed for productive protein surface recognition (even fewer 
than the QXPEHU LGHQWLILHG LQ WKH ³GHOHWLRQ´ VWXG\ E\ WKH
Ohkanda group using heteroleptic complexes),[41]  
 
Table 3. Parameters derived from the Güntelberg approximation of Debye-
Hückel analysis for the binding of complexes 1 and 2 to cyt c and literature 
values for CCP in similar conditions[52] 
 Complex 1 Complex 2 CCP[52] 
Kd0 / nM 253 ± 5 1.11 ± 0.21 40.7 ± 23.0 
Z1Z2 25.9 ± 1.9 35.6 ± 1.3 28.8 ± 4.8 
 
Table 4. Binding affinities for complex 2 to cyt c in different buffers. All 
buffers were at 5 mM concentration, pH 7.5 
Buffer Kd / nM 
Sodium phosphate 42.9 ± 3.1 
Potassium phosphate 26.2 ± 3.1 
MOPS 35.2 ± 3.1 
HEPES 31.2 ± 3.1 
Tris 106.3 ± 32.6 
btp 133.5 ± 37.4 
 
Differences in affinity between cyt c and complex 2 were 
also studied in different buffers (Table 4). Variation in affinity 
might discriminate different contributions to binding as negatively 
charged anions must be displaced from cyt c and positively 
charged cations from complex 2. In potassium and sodium 
phosphate no difference in affinity between complex 2 and cyt c 
is observed, indicating interaction of the cationic buffer 
components with complex 2 are not significant. For binding of 
cyt c to complex 2 in phosphate or sulfonic acid buffers (MOPS 
and HEPES), similar affinities are also observed. This suggests 
the nature of the anion and, more importantly, hydrophobicity of 
the buffer are not significant in mediating molecular recognition, 
and, reinforce the conclusions gleaned from Debye-Hückel 
analysis that the interaction is dominated by electrostatic 
contributions. For the tris buffers (btp and tris) a small decrease 
in binding affinity is observed. Although a difference in behavior 
due to the counter chloride anion cannot be excluded, this may 
be due to the ability of btp and tris to make different interactions 
with both cyt c and complex 2; in addition to the ammonium 
function, the hydroxyls on the buffer may make chelating 
hydrogen-bonds with charged residues on either.  
Cyt c is a stable protein that does not unfold over a wide 
range of pHs, however its ionization state is affected by pH,[53]  
hence the pH of the solution was expected to affect recognition 
of cyt c by Ru(II)(bpy)3 complexes. To investigate the binding 
affinity between complex 2 and cyt c over a broad pH regime, 
btp was used as it allows for a pH range of 6.5±9.5. The affinity 
follows an inverted bell shaped profile (Figure 4A), which maps 
reasonably well onto the ionization state of cyt c (Figure 4A 
inset).[53] The affinity between pH 7.0±8.5 is relatively constant 
with decreased binding observed at pH 6.5 and pH 9.0. 
Residues that become protonated/deprotonated in this pH 
regime are His-33 and Lys-79 respectively.[53] Lys-79 (green) is 
at the haem exposed edge (Figure 4B) where binding of 
complex 2 is thought to occur, whereas His-33 (pink) is on the 
distal face of cyt c. A number of reasons for a decrease in 
binding affinity at this pH are possible: (a) complex 2 binds to a 
different or multiple sites on cyt c, (b) binding of complex 2 
causes subtle conformational changes that transmit to the distal 
face of cyt c affecting the pKa of His-33, (c) protonation of His-33 
causes subtle conformational changes that affect binding 
interactions on the haem exposed edge, or (d) the protonation 
state of complex 2 is changed at pH 6.5. More careful analysis 
of the pH-Kd/ionization state profiles reveals a discrepancy. The 
ionization state of cyt c drops at pH 8.0 rather than pH 8.5 where 
the binding diminishes, suggesting that binding of complex 2 
might mask Lys-79 and increase its pKa. In contrast there is no 
difference in the profiles for Kd and ionization state of cyt c in the 
lower pH range suggesting that the pKa of His-33 is not affected 
by binding and that loss of affinity more likely derives from a 
change in ionization state on complex 2.  
Figure 4. Effect of pH on the binding of complex 2 to cyt c. (a) Binding affinity 
over the range pH 6.5 ± LQVHWWKHHOHFWURVWDWLFLQWHUDFWLRQIDFWRUȦRIF\W
c over a range of pHs (base limb of titration curve)[53], (b) Cyt c structure (PDB 
ID 1U75)[54] with residues that become protonated at pH 6.5 and 9.0, His-33 
(pink) and Lys-79 (green) respectively  
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Figure 5. 1H-15N HSQC NMR data of complex 1 binding to cyt c. (A) Region of the overlaid HSQC spectrum of cyt c (red) and cyt c with 0.5 eq complex 1 (blue), 
Inset shows zoom in of part of the spectrum, showing some peaks staying the same, some having shifted and one disappearing. (B) 1H-15N chemical shift 
differences ('G) for the different amino acid residues with and without complex 1. Gaps are for prolines and unassigned amino acids, red bars show amino acids 
for which the signal disappears due to significant line-broadening of NH cross-peaks on addition of complex 1. (C) Chemical shift perturbation map of cyt c, 
molecular surface of cyt c generated from PyMol (PDB ID 1U75),[54] with coloring corresponding to the extent of chemical shift changes ('G) on addition of the 
complex. Amino acids with 15N-1H resonances that disappear in dark red, exhibit large chemical shift changes ǻį!LQUHGmoderate changes ǻį!LQ
orange, small changes ǻį!LQ\HOORZ-orange and very small chemical shift changes ǻį!LQ\HOORZ'SHUWXUEDWLRQPDSRIF\WFDV&LQFRPSOH[
with CCP (purple), this view corresponds to that of the central top image in Figure 5C, (PDB ID 1U75)[34] 
 
High-Field NMR reveals complexes 1 and 2 bind to the CCP 
binding site on cyt c 
While the pH data provide some crude structural information on 
the cyt c binding site of Ru(II)(bpy)3 complexes, more detailed 
residue-specific, atomic-level data were sought. To identify the 
binding site of complex 1 and 2 on cyt c, a sensitivity-enhanced 
natural abundance 1H-15N HSQC spectrum of cyt c in the 
presence and absence of complex 1 was recorded, using a 950 
MHz NMR spectrometer. 2 mM sodium ascorbate was added to 
the buffer, to reduce the iron in cyt c from paramagnetic Fe(III) to 
diamagnetic Fe(II), thus minimizing its influence on the 
spectrum, i.e. paramagentic line broadening. The binding of the 
complexes to cyt c for reduced versus oxidized cyt c is similar 
(for complex 2, Kd = 92.4 ± 5.5 and 49.6 ± 13.3 nM respectively, 
in 5 mM phosphate, 2 mM sodium ascorbate, 0.2 mg mL-1 BSA).  
The assignment of the 1H-15N HSQC spectrum of horse 
heart cyt c has previously been obtained.[55] Upon addition of 
complex 1, the NMR data show several cross-peaks having 
disappeared, while others display chemical shift changes 
ranging from 0.015-0.05 ppm indicating the presence of protein-
ligand interactions (Figure 5A and 5B). When these chemical 
shift changes are mapped onto the structure of cyt c from the cyt 
c/ CCP crystal structure,[54] the data indicate binding occurs 
predominantly to one side of the haem group, with the opposite 
face having very few amino acids with sizeable shifts in their 
HSQC peaks (Figure 5C). The binding site is in a similar location 
to that of carboxylic acid functionalized porphyrins.[18] In 
comparison to the cyt c/ CCP interaction (Figure 5D), it can be 
seen that the amino acids whose cross-peaks have shifted are 
in and around the PPI interface, indicating complex 1 is an 
effective mimic of CCP, binding at the same face and capable of 
acting as an orthosteric inhibitor of the interaction. 
Attempts to acquire data in the presence of complex 2 
were difficult due to the high affinity binding and the relatively 
high concentrations required for natural abundance NMR. At 1:1 
ratios of cyt c and complex 2, data could not be obtained due to 
ChemBioChem 10.1002/cbic.201600552
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the formation of oligomers and a concomitant loss of NMR signal 
intensity, caused by significant line-broadening.This unsurprising 
to us as given the potential for aggregation at higher 
concentrations and the observation of additional binding modes 
in NMR studies using porphyrins.[18] Further evidence of an 
additional/alternative binding mode for the larger complex 2, is 
the visualization of a second binding event for complex 2 with 
yeast cyt c, but a single binding event for complex 1 (See ESI, 
Fig. S2). Even at 1:2 equivalents complex 2:cyt c multiple 
signals disappeared, so detailed information as to the binding 
site could not be gleaned, however of the signals present, 
chemical shift changes were detected for regions of the protein 
backbone located on the same binding face as for complex 1, 
and on the haem exposed edge.   
Conclusions 
We have performed a detailed study on the cyt c binding 
properties of two synthetic Ru(II)(bpy)3 complexes 1 and 2. The 
ruthenium complexes are potent ligands for selective protein 
surface recognition of cyt c and capable of inhibiting the cyt c/ 
CCP PPI. Binding is shown to be entropically favorable and 
driven by complementary electrostatic interactions between the 
basic protein and acidic Ru(II)(bpy)3 complexes. This profile is 
consistent with accurate mimicry of the cyt c binding properties 
of CCP. Higher-affinity recognition of the protein target can be 
achieved through the addition of further acidic motifs on the 
Ru(II)(bpy)3 complexes allowing additional enthalpically 
favorable electrostatic interactions to occur. Finally, NMR 
experiments establish that the Ru(II)(bpy)3 complexes 1 and 2 
bind to the solvent exposed cyt c surface further underscoring 
the ability of the complexes to act as mimics of CCP and 
confirming an orthosteric mode of PPI inhibition. These studies 
highlight the value of detailed analyses of protein-surface 
recognition by supramolecular hosts in terms of rationalizing 
structure function relationships, and informing subsequent 
designs. Moreover the conclusions of this study point to a future 
need for syntheses/ assembly of asymmetrically functionalized 
Ru(II)(bpy)3 complexes to maximize productive protein-ligand 
contacts and selectivity of protein surface recognition. This and 
the application of our approach to therapeutically attractive 
protein targets will form the basis of future studies by our group. 
Experimental Section 
Synthesis 
Synthesis was adapted from literature.[36] A representative synthesis of 
complex 1 is shown below. The synthesis of complex 2 is described in 
the supplementary information. 
 (2S,2'R)-tetra-tert-butyl-2,2'-(([2,2'-bipyridine]-4,4'-dicarbonyl)bis 
(azanediyl)) disuccinate 
¶-bipyridine-¶-dicarboxylic acid (100 mg, 0.400 mmol), triethylamine 
(1 drop) and thionyl chloride (4 mL) were heated under reflux for 16 
hours. The mixture was cooled to room temperature and the thionyl 
chloride removed in vacuo to yield the acid chloride as an orange-red 
solid.  The dry acid chloride was then redissolved in dry chloroform (20 
mL) and added dropwise to a stirred solution of di-tert butyl L-aspartic 
acid.HCl (253 mg, 0.901 mmol) and triethylamine (0.25 mL, 1.80 mmol) 
in dry chloroform at 0°C. The reaction mixture was warmed to room 
temperature and refluxed for 48 hours. The mixture was cooled to room 
temperature and the solvent removed to yield the crude product as a 
brown oil. This was purified by flash column chromatography (3 % - 6 % 
MeOH in CHCl3) to yield the product as a yellow solid (262 mg, 0.375 
mmol, 91 %); 1H NMR (300 MHz, CDCl3) ? ppm 1.49 (s, 18 H, H1/H2), 
1.52 (s, 18 H), 2.91 (dd, J=17.2, 4.3 Hz, 2 H), 3.04 (m, J=17.2, 4.3 Hz, 
2H), 4.92 (dt, J=7.5, 4.3 Hz, 2 H), 7.46 (d, J=7.5 Hz, 2 H), 7.77 (dd, 
J=5.0, 1.65 Hz, 2 H), 8.78 (app. s, 2 H), 8.83 (d, J=5.0 Hz, 2 H); 13C NMR 
(126 MHz, CDCl3) ? ppm 28.0, 28.1, 37.5, 49.7, 81.9, 82.8, 118.0, 121.8, 
142.3, 150.1, 156.3, 165.1, 169.5, 170.2 ; IR (solid state) 3346, 2975, 
2928, 1723, 1650; ESI-HRMS: found m/z 699.3615, [C36H51N4O10]+ 
requires 699.3599 
7ULV 6¶5-tetra-tert-butyl-¶-(>¶-bipyridine]-¶-
dicarbonyl)bis (azanediyl))disuccinate) ruthenium(II) dinitrate 
 (2S,2'R)-tetra-tert-butyl-2,2'-(([2,2'-bipyridine]-4,4'-dicarbonyl)bis 
(azanediyl)) disuccinate (300 mg, 0.429 mmol), 
(dimethylsulfoxide)dichlororuthenium (II) (65 mg, 0.134 mmol), silver 
nitrate (46 mg, 0.268 mmol) and ethanol (20 mL) were heated under 
reflux for 7 days. After which time the reaction mixture was filtered hot 
and concentrated. The red solid was then loaded onto an SP Sephadex 
column and eluted with 1:1 acetone: 0.1 M NaCl solution and all the red 
fractions collected and concentrated. The combined red fractions were 
redissolved in acetone and filtered to remove sodium chloride, and this 
was repeated until no more white salt was visible in the concentrated 
sample. The complex was then purified by flash chromatography (1 ± 3 
% MeOH in CHCl3) and the red fractions collected. These were 
concentrated, redissolved in CHCl3 and extracted with water to yield the 
product as a red solid (77 mg, 0.034 mmol, 25 %); 1H NMR (300 MHz, 
Acetone) ? ppm 2.10 (app s, 108 H), 2.81 - 3.07 (m, 24 H), 4.79 - 5.07 
(m, 24 H), 7.89 (dd, J = 15.8, 6.6 Hz, 12 H), 8.37 (dd, J = 15.8, 8.5 Hz, 12 
H), 8.82 - 8.98 (m, 12 H); 13C NMR (126 MHz, CDCl3) ? ppm 27.9, 28.1, 
29.6, 37.1, 50.9, 81.4, 82.4, 123.5, 143.5, 157.2, 157.3, 162.2, 169.2, 
169.4, 170.0; ESI-HRMS: found m/z 1098.4854, [C108H150N12O30Ru]2+ 
requires 1098.4822; ?max (MeOH): 306 nM (?/ dm3 mol-1 cm-1 240 723 
981) 
Tris (2S,2'R)-2,2'-(([2,2'-bipyridine]-4,4'-dicarbonyl)bis 
(azanediyl))disuccinicacid) ruthenium(II) ditrifluoroacetate, complex 
1 
Tris ((2S,2'R)-tetra-tert-butyl -2,2'-(([2,2'-bipyridine] -4,4'-dicarbonyl) 
bis(azanediyl)) disuccinate) ruthenium(II) dinitrate(68 mg, ), TFA (4.5 mL) 
and water (0.5 mL) were stirred for 3 days. The reaction mixture was 
then concentrated in vacuo to yield the product as a red-black solid (57 
mg, 0.0294 mmol, 98 %); 1H NMR (500 MHz, D2O) ɷ ppm 8.97 (s, 1 H), 
7.90 (s, 1 H), 7.70 (s, 1 H), 4.61 (s, 1 H), 2.78 (s, 1 H), 2.67 (s, 1 H¶), ; IR 
(solid state) 3182, 3050, 1648; ESI-HRMS: found m/z 762.1081, 
[C60H54N12O30Ru]2+ requires 762.1056; 
Protein Expression and Purification 
Cytochrome c peroxidase (CCP) was overexpressed in Escherichia coli 
(E. coli) using the plasmid pT7CCP) in which expression was placed 
under the control of T7 RNA polymerase. The enzyme was isolated from 
E. coli BL21 (DE3) as an apo-enzyme which was purified according to 
the literature.[1]. A 2 L culture of the expression strain supplemented with 
ampicillin was grown at 37 °C for 36 h in a medium containing (per litre) 
10 g of bactotryptone, 8 g of yeast extract, 5 g of NaCl, 1 mL of glycerol, 
and 100 mg of ampicillin. Subsequent steps were performed at 4 °C. The 
cells were harvested by centrifugation at 6000g for 10 min, resuspended 
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in 40 mL of buffer containing 200 mM potassium phosphate pH 7.5, 2 
tablets of Roche protease inhibitor tablets mini, and 1 mM EDTA, and 
lysed by passing through a cell disrupter. The lysate was diluted with 100 
mL of cold H2O. Enough ascorbic acid was added to bring the buffer to 
5mM. To improve the ratio of the soret band to the band at 280 nm of 
FeCCP, an excess of haem was added, 80 mg of haemin/ 12 L culture 
was dissolved in a minimal amount of 100 mM KOH in the dark, and 
diluted 10 times with 100 mM potassium phosphate, pH 6. The haem 
solution was gradually added to clarified lysate on ice over 30 minutes 
with gentle stirring, then stirred on ice for 1 hour in the dark. The excess 
haem was then precipitated by first acidifying the solution with 100 mM 
acetic acid to pH 5.0, and freezing the solution in dry ice until just frozen. 
The solution was then allowed to just thaw with gentle shaking at 37 °C 
The solution was centrifuged at 10 000 ± 12 000 rpm for 20 minutes and 
the supernatant decanted. The clear supernatant was loaded onto a 
DEAE-Sepharose CL-6B (3 x 5 cm) column equilibrated with 50 mM 
potassium phosphate, pH 6, and washed with the same buffer. After 
elution with 500 mM potassium phosphate, pH 6, the enzyme-containing 
fractions were diluted with an equal volume of cold H2O and 
concentrated to approximately 1 mL by ultrafiltration (Amicon YM-10 
membrane). The sample was centrifuged at 12000g for 2 min to remove 
insoluble material, loaded onto a Sephadex G-75 superfine column (3 x 
60 cm) and eluted with 100 mM potassium phosphate, pH 6, and 1 mM 
EDTA. The fractions containing A408/A280 >1.1 were pooled (protein 
concentration was determined from the molar absorptivity; İ P0-1 
cm-1, at 282 nm). 
In order to exchange the haem for Zn porphyrin, the haem was removed 
using the acid butanone method[2] with minor modifications. A ~1 mM 
solution of haem CCP in 100 mM potassium phosphate buffer was 
diluted with 4 volumes of ice-cold water. The CCP solution was brought 
to 100 mM fluoride by addition of 1 M KF solution, breaking the haem-
protein linkage and turning the solution green. The haem was removed 
by lowering the pH of the solution to pH 3.2-3.3 by adding ice cold 0.1 M 
HCl dropwise, with gentle stirring. The haem was then extracted by 
adding an equal volume of ice cold 2-butanone, shaking for 30 seconds 
and centrifuged for 1 minute at 1000g. The brown layer was siphoned 
away and the extraction repeated until the aqueous layer became 
colourless. The resulting apoCCP solution was diluted with a half volume 
of cold water and dialysed against 2-3 changes of 10 mM NaHCO3 
solution.  It was then dialysed against water, changing the outer solution 
every 2 hours until the bag no longer smelt of butanone (~24 hours), 
followed by dialysis into 10 mM Tris-HCl, pH 7. A 4:1 excess of porphyrin 
was dissolved in 200-500 ?L of 100 mM KOH and diluted 5-10 times with 
water. The porphyrin solution was added to the protein solution, and the 
protein solution titrated to pH 7.8 with 100 mM KOH. In the dark, the 
alkaline porphyrin solution was added dropwise with gentle stirring to 
apoCCP until ~2 fold excess of porphyrin was present. The solution was 
left to stand at near pH 8 for 20-30 minutes than brought to pH 6.5-7.0 by 
addition of 1 M monobasic potassium phosphate. The protein was 
exchange into 25 mM potassium phosphate, pH 6.5 and concentrated by 
ultracentrifugation to 0.5-1.0 mM CPP. The protein was loaded onto a 
small column of DEAE Sepharose CL-6B, pre-equilibrated with 25 mM 
potassium phosphate, pH 6.5. The column was rinsed with around half a 
volume of loading buffer, and the metalloporphyrin CCP eluted with 0.6 M 
potassium phosphate, pH 6.5.  
Inhibition of Cyt c/CCP by fluorescence recovery  
To a 500 µL micro fluorescence cell (Hellma Analytics) containing 500 µL 
of 2 µM ZnCCP (H280 = 55 mM-1cm-1) was added 1 eq of cytochrome c, in 
DVROXWLRQFRQWDLQLQJȝ0=Q&&3HTXLYDOHQWVRIFRPSOH[2 were then 
added. Fluorescence spectra where taken at each point (ex. 430 nm). A 
separate comparative spectra for complex 2 was taken using identical 
instrument settings 
Luminescence quenching assays 
All stocks for luminescence intensity assays were made up in 5 mM 
phosphate buffer (pH 7.5).  Ruthenium complex stocks were made up to 
2 mM. Horse heart and yeast cyt c was obtained from Sigma Aldrich, and 
used without further purification.  A cytochrome c stock was made up to 
~1 mM, and the concentration accurately determined using the molar 
extinction coefficient at 550 nm of 2.95 × 104 mol-1 dm3 cm-1 for horse 
heart cyt c [56] and 2.11 × 104 mol-1 dm3 cm-1 for yeast cyt c[56] after 
reduction by addition of one microspatula of sodium dithionite. Assays 
with oxidized cyt c in ascorbate containing buffer used cyt c oxidized with 
K3Fe(CN)6 followed by dialysis into 5 mM sodium phosphate, 2 mM 
sodium ascorbate, pH 7.5 buffer, to remove the excess K3(CN)6. The 
concentration of oxidized cyt c was determined by using the molar 
extinction coefficient at 410 nm of 1.061 × 105 mol-1 dm3 cm-1[57].All 
buffers used were at 5 mM concentration, 0.2 mg mL-1 BSA, pH 7.5, 
unless otherwise stated.  
Fluorometer luminescence quenching assays were measured on a Jobin-
Yvon Spex Fluorolog-3 fluorometer. Measurements were taken in a 4 mL 
quartz cuvette with excitation at 467 nm and emission measured over the 
range 575 ± 675 nm, with 10 nm slit widths on both excitation and 
emission. Peak maxima were recorded over the entire cyt c 
concentration gradient. 
Plate reader luminescence quenching assays, were performed using a 
Perkin Elmer EnVisionTM 2103 MultiLabel plate reader, with excitation at 
467 nm, and emission at 630 nm fixed wavelength. A 2/3 dilution regime 
in a 384 well plate (Optiplate) was used (total well volume 50 µL), with 
each result measured in triplicate. The Kd ranges possible for this assay 
is ~5 nM ± aȝ0 
In all assays the ruthenium complex concentration was kept constant, 
with the concentration of cyt c being varied through the assay, as 
described below. Results obtained were fitted, using Origin9, to a 1:1 
binding isotherm: 
 
 
Where I = change in relative luminescence intensity (I/I0), m = maximum 
value of I, a = concentration of complex, K = dissociation constant, b = 
concentration of protein added 
Protein NMR 
 
Sensitivity enhanced 1H-15N HSQC NMR correlation spectra of ligand-
bound and unbound forms of cyt c, purchased from Sigma Aldrich, were 
carried out at natural abundance using a 950 MHz Bruker AscendTM 
Aeon spectrometer operating at a proton (1H) resonance frequency of 
950.13 MHz equipped with a Bruker TCI triple-resonance cryo-probe. 
NMR acquisitions were carried out in 5 mM sodium phosphate, 2 mM 
sodium ascorbate, pH 7.25 buffer. For cyt c alone, spectra were taken at 
2 mM protein concentration. With complex 1, 1 mM cyt c and 0.5 mM 
complex 1 were used, to a total volume of 600 ?L. Spectra were 
analysed using the CcpNmr Analysis software package and the chemical 
shift perturbations were calculated as the square root of the sum of the 
isotope weighted shift differences squared (Eq. 4), 
 
ZKHUHǻį is the overall change in chemical shift, ǻįN is the change in the 
QLWURJHQ GLPHQVLRQ DQG ǻįH is the change in the proton dimension, 
respectively. The change in the proton dimension is scaled by the ratio of 
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the gyromagnetic ratio of 15N (ȖN) and 1H (ȖH) to account for the larger 
chemical shift range of nitrogen. 
Keywords: Protein-protein interactions  receptors  
supramolecular chemistry  molecular recognition  protein 
surface recognition 
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